New targeted and epigenetic therapeutic strategies for the treatment of uveal melanoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2022-03-02

AUTHORS

Alexander Z. Wei, Ashray B. Maniar, Richard D. Carvajal

ABSTRACT

Uveal melanoma (UM) is a rare, genetically bland ocular malignancy with excellent local treatment options, but no disease-specific therapies are approved for use in the metastatic setting by the Food and Drug Administration. Metastatic UM (mUM) confers a prognosis of ~15 months. Unlike cutaneous melanoma, UM is poorly responsive to checkpoint inhibitors and cytotoxic chemotherapy highlighting the importance of clarifying vulnerable disease-specific mechanisms, such as cell cycle or metabolic pathways necessary for tumor growth and survival. The elucidation of signaling pathways downstream of the frequently mutated GNA GTPase such as PKC/MAPK/ERK/MEK, PI3K/AKT, and YAP-Hippo have offered potential targets. Potentially druggable epigenetic targets due to BAP1-mutated UM have also been identified, including proteins involved with histone deacetylation and DNA splicing. This review describes the preclinical rationale for the development of targeted therapies and current strategies currently being studied in clinical trials or will be in the near future. More... »

PAGES

1-8

References to SciGraph publications

  • 2019-12-06. Structural basis of ligand selectivity and disease mutations in cysteinyl leukotriene receptors in NATURE COMMUNICATIONS
  • 2016-07-23. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors in INVESTIGATIONAL NEW DRUGS
  • 2013-10-21. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations in ONCOGENE
  • 2019-06-28. The genetic evolution of metastatic uveal melanoma in NATURE GENETICS
  • 2018-01-09. Punctuated evolution of canonical genomic aberrations in uveal melanoma in NATURE COMMUNICATIONS
  • 2021-03-17. Targeting FAK in anticancer combination therapies in NATURE REVIEWS CANCER
  • 2019-08-16. Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma in NPJ SYSTEMS BIOLOGY AND APPLICATIONS
  • 2005-05-31. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS in BRITISH JOURNAL OF CANCER
  • 2004-07. Insulin-like growth factors and neoplasia in NATURE REVIEWS CANCER
  • 2021-02-15. Involvement of mutant and wild-type CYSLTR2 in the development and progression of uveal nevi and melanoma in BMC CANCER
  • 2013-01-13. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma in NATURE GENETICS
  • 2010-06-08. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy in BRITISH JOURNAL OF CANCER
  • 2013-06-23. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3 in NATURE GENETICS
  • 2015-12-14. The experimental power of FR900359 to study Gq-regulated biological processes in NATURE COMMUNICATIONS
  • 2016-06-07. Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status in NATURE MEDICINE
  • 2008-12-10. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi in NATURE
  • 2010-01-27. Chromatin remodelling during development in NATURE
  • 2018-02-19. Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma in MOLECULAR CANCER
  • 2016-02-04. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage in NATURE COMMUNICATIONS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/s41417-022-00443-8

    DOI

    http://dx.doi.org/10.1038/s41417-022-00443-8

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1145975064

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/35236928


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Columbia University Irving Medical Center, New York, New York, USA", 
              "id": "http://www.grid.ac/institutes/grid.239585.0", 
              "name": [
                "Columbia University Irving Medical Center, New York, New York, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Wei", 
            "givenName": "Alexander Z.", 
            "id": "sg:person.011251642454.11", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011251642454.11"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Columbia University Irving Medical Center, New York, New York, USA", 
              "id": "http://www.grid.ac/institutes/grid.239585.0", 
              "name": [
                "Columbia University Irving Medical Center, New York, New York, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Maniar", 
            "givenName": "Ashray B.", 
            "id": "sg:person.011675624160.73", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011675624160.73"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Columbia University Irving Medical Center, New York, New York, USA", 
              "id": "http://www.grid.ac/institutes/grid.239585.0", 
              "name": [
                "Columbia University Irving Medical Center, New York, New York, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Carvajal", 
            "givenName": "Richard D.", 
            "id": "sg:person.0726366600.25", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1186/s12885-021-07865-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1135369909", 
              "https://doi.org/10.1186/s12885-021-07865-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s12943-018-0795-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1101066796", 
              "https://doi.org/10.1186/s12943-018-0795-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/onc.2013.418", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019096299", 
              "https://doi.org/10.1038/onc.2013.418"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature08911", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025477952", 
              "https://doi.org/10.1038/nature08911"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm.4098", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1046002996", 
              "https://doi.org/10.1038/nm.4098"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41588-019-0440-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1117623763", 
              "https://doi.org/10.1038/s41588-019-0440-9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bjc.6602598", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051793685", 
              "https://doi.org/10.1038/sj.bjc.6602598"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41467-017-02428-w", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1100179001", 
              "https://doi.org/10.1038/s41467-017-02428-w"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc1387", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015516287", 
              "https://doi.org/10.1038/nrc1387"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bjc.6605714", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013296980", 
              "https://doi.org/10.1038/sj.bjc.6605714"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ncomms10156", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043043138", 
              "https://doi.org/10.1038/ncomms10156"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10637-016-0377-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040010442", 
              "https://doi.org/10.1007/s10637-016-0377-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41467-019-13348-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1123153093", 
              "https://doi.org/10.1038/s41467-019-13348-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng.2674", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034318026", 
              "https://doi.org/10.1038/ng.2674"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature07586", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018711414", 
              "https://doi.org/10.1038/nature07586"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41568-021-00340-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1136443344", 
              "https://doi.org/10.1038/s41568-021-00340-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng.2523", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004149711", 
              "https://doi.org/10.1038/ng.2523"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ncomms10615", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006408398", 
              "https://doi.org/10.1038/ncomms10615"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41540-019-0107-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1120337444", 
              "https://doi.org/10.1038/s41540-019-0107-2"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2022-03-02", 
        "datePublishedReg": "2022-03-02", 
        "description": "Uveal melanoma (UM) is a rare, genetically bland ocular malignancy with excellent local treatment options, but no disease-specific therapies are approved for use in the metastatic setting by the Food and Drug Administration. Metastatic UM (mUM) confers a prognosis of ~15 months. Unlike cutaneous melanoma, UM is poorly responsive to checkpoint inhibitors and cytotoxic chemotherapy highlighting the importance of clarifying vulnerable disease-specific mechanisms, such as cell cycle or metabolic pathways necessary for tumor growth and survival. The elucidation of signaling pathways downstream of the frequently mutated GNA GTPase such as PKC/MAPK/ERK/MEK, PI3K/AKT, and YAP-Hippo have offered potential targets. Potentially druggable epigenetic targets due to BAP1-mutated UM have also been identified, including proteins involved with histone deacetylation and DNA splicing. This review describes the preclinical rationale for the development of targeted therapies and current strategies currently being studied in clinical trials or will be in the near future.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/s41417-022-00443-8", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1112008", 
            "issn": [
              "0929-1903", 
              "1476-5500"
            ], 
            "name": "Cancer Gene Therapy", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }
        ], 
        "keywords": [
          "druggable epigenetic targets", 
          "epigenetic therapeutic strategies", 
          "ERK/MEK", 
          "PI3K/Akt", 
          "histone deacetylation", 
          "epigenetic targets", 
          "cell cycle", 
          "DNA splicing", 
          "metabolic pathways", 
          "potential target", 
          "uveal melanoma", 
          "pathway", 
          "disease-specific mechanisms", 
          "tumor growth", 
          "GTPase", 
          "splicing", 
          "therapeutic strategies", 
          "MEK", 
          "metastatic UM", 
          "Akt", 
          "protein", 
          "target", 
          "deacetylation", 
          "BAP1", 
          "metastatic uveal melanoma", 
          "disease-specific therapies", 
          "elucidation", 
          "local treatment options", 
          "preclinical rationale", 
          "inhibitors", 
          "current strategies", 
          "growth", 
          "metastatic setting", 
          "checkpoint inhibitors", 
          "cytotoxic chemotherapy", 
          "treatment options", 
          "cutaneous melanoma", 
          "clinical trials", 
          "ocular malignancy", 
          "melanoma", 
          "Drug Administration", 
          "mechanism", 
          "survival", 
          "near future", 
          "cycle", 
          "therapy", 
          "food", 
          "strategies", 
          "development", 
          "importance", 
          "chemotherapy", 
          "prognosis", 
          "malignancy", 
          "administration", 
          "review", 
          "trials", 
          "months", 
          "treatment", 
          "options", 
          "setting", 
          "rationale", 
          "future", 
          "use"
        ], 
        "name": "New targeted and epigenetic therapeutic strategies for the treatment of uveal melanoma", 
        "pagination": "1-8", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1145975064"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/s41417-022-00443-8"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "35236928"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/s41417-022-00443-8", 
          "https://app.dimensions.ai/details/publication/pub.1145975064"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:44", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_939.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/s41417-022-00443-8"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41417-022-00443-8'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41417-022-00443-8'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41417-022-00443-8'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41417-022-00443-8'


     

    This table displays all metadata directly associated to this object as RDF triples.

    208 TRIPLES      21 PREDICATES      105 URIs      78 LITERALS      5 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/s41417-022-00443-8 schema:about anzsrc-for:11
    2 anzsrc-for:1112
    3 schema:author Ndf9d067184d84247aa212cd6d6af7a36
    4 schema:citation sg:pub.10.1007/s10637-016-0377-0
    5 sg:pub.10.1038/nature07586
    6 sg:pub.10.1038/nature08911
    7 sg:pub.10.1038/ncomms10156
    8 sg:pub.10.1038/ncomms10615
    9 sg:pub.10.1038/ng.2523
    10 sg:pub.10.1038/ng.2674
    11 sg:pub.10.1038/nm.4098
    12 sg:pub.10.1038/nrc1387
    13 sg:pub.10.1038/onc.2013.418
    14 sg:pub.10.1038/s41467-017-02428-w
    15 sg:pub.10.1038/s41467-019-13348-2
    16 sg:pub.10.1038/s41540-019-0107-2
    17 sg:pub.10.1038/s41568-021-00340-6
    18 sg:pub.10.1038/s41588-019-0440-9
    19 sg:pub.10.1038/sj.bjc.6602598
    20 sg:pub.10.1038/sj.bjc.6605714
    21 sg:pub.10.1186/s12885-021-07865-x
    22 sg:pub.10.1186/s12943-018-0795-z
    23 schema:datePublished 2022-03-02
    24 schema:datePublishedReg 2022-03-02
    25 schema:description Uveal melanoma (UM) is a rare, genetically bland ocular malignancy with excellent local treatment options, but no disease-specific therapies are approved for use in the metastatic setting by the Food and Drug Administration. Metastatic UM (mUM) confers a prognosis of ~15 months. Unlike cutaneous melanoma, UM is poorly responsive to checkpoint inhibitors and cytotoxic chemotherapy highlighting the importance of clarifying vulnerable disease-specific mechanisms, such as cell cycle or metabolic pathways necessary for tumor growth and survival. The elucidation of signaling pathways downstream of the frequently mutated GNA GTPase such as PKC/MAPK/ERK/MEK, PI3K/AKT, and YAP-Hippo have offered potential targets. Potentially druggable epigenetic targets due to BAP1-mutated UM have also been identified, including proteins involved with histone deacetylation and DNA splicing. This review describes the preclinical rationale for the development of targeted therapies and current strategies currently being studied in clinical trials or will be in the near future.
    26 schema:genre article
    27 schema:isAccessibleForFree false
    28 schema:isPartOf sg:journal.1112008
    29 schema:keywords Akt
    30 BAP1
    31 DNA splicing
    32 Drug Administration
    33 ERK/MEK
    34 GTPase
    35 MEK
    36 PI3K/Akt
    37 administration
    38 cell cycle
    39 checkpoint inhibitors
    40 chemotherapy
    41 clinical trials
    42 current strategies
    43 cutaneous melanoma
    44 cycle
    45 cytotoxic chemotherapy
    46 deacetylation
    47 development
    48 disease-specific mechanisms
    49 disease-specific therapies
    50 druggable epigenetic targets
    51 elucidation
    52 epigenetic targets
    53 epigenetic therapeutic strategies
    54 food
    55 future
    56 growth
    57 histone deacetylation
    58 importance
    59 inhibitors
    60 local treatment options
    61 malignancy
    62 mechanism
    63 melanoma
    64 metabolic pathways
    65 metastatic UM
    66 metastatic setting
    67 metastatic uveal melanoma
    68 months
    69 near future
    70 ocular malignancy
    71 options
    72 pathway
    73 potential target
    74 preclinical rationale
    75 prognosis
    76 protein
    77 rationale
    78 review
    79 setting
    80 splicing
    81 strategies
    82 survival
    83 target
    84 therapeutic strategies
    85 therapy
    86 treatment
    87 treatment options
    88 trials
    89 tumor growth
    90 use
    91 uveal melanoma
    92 schema:name New targeted and epigenetic therapeutic strategies for the treatment of uveal melanoma
    93 schema:pagination 1-8
    94 schema:productId N104852a36ae541e19aa28b6a38cb42ae
    95 N4c56dea153d041f293934c4968e54afe
    96 Nbf5b2d88d6f642759f2ef1660a64d6ee
    97 schema:sameAs https://app.dimensions.ai/details/publication/pub.1145975064
    98 https://doi.org/10.1038/s41417-022-00443-8
    99 schema:sdDatePublished 2022-12-01T06:44
    100 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    101 schema:sdPublisher N66fc0431c8d440bdb32f19a76e204603
    102 schema:url https://doi.org/10.1038/s41417-022-00443-8
    103 sgo:license sg:explorer/license/
    104 sgo:sdDataset articles
    105 rdf:type schema:ScholarlyArticle
    106 N104852a36ae541e19aa28b6a38cb42ae schema:name doi
    107 schema:value 10.1038/s41417-022-00443-8
    108 rdf:type schema:PropertyValue
    109 N216bb9a83631469aabac4ec69ceee8a8 rdf:first sg:person.011675624160.73
    110 rdf:rest N316ca019b6fa4d759a6ad7c0e36d87ea
    111 N316ca019b6fa4d759a6ad7c0e36d87ea rdf:first sg:person.0726366600.25
    112 rdf:rest rdf:nil
    113 N4c56dea153d041f293934c4968e54afe schema:name dimensions_id
    114 schema:value pub.1145975064
    115 rdf:type schema:PropertyValue
    116 N66fc0431c8d440bdb32f19a76e204603 schema:name Springer Nature - SN SciGraph project
    117 rdf:type schema:Organization
    118 Nbf5b2d88d6f642759f2ef1660a64d6ee schema:name pubmed_id
    119 schema:value 35236928
    120 rdf:type schema:PropertyValue
    121 Ndf9d067184d84247aa212cd6d6af7a36 rdf:first sg:person.011251642454.11
    122 rdf:rest N216bb9a83631469aabac4ec69ceee8a8
    123 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    124 schema:name Medical and Health Sciences
    125 rdf:type schema:DefinedTerm
    126 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    127 schema:name Oncology and Carcinogenesis
    128 rdf:type schema:DefinedTerm
    129 sg:journal.1112008 schema:issn 0929-1903
    130 1476-5500
    131 schema:name Cancer Gene Therapy
    132 schema:publisher Springer Nature
    133 rdf:type schema:Periodical
    134 sg:person.011251642454.11 schema:affiliation grid-institutes:grid.239585.0
    135 schema:familyName Wei
    136 schema:givenName Alexander Z.
    137 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011251642454.11
    138 rdf:type schema:Person
    139 sg:person.011675624160.73 schema:affiliation grid-institutes:grid.239585.0
    140 schema:familyName Maniar
    141 schema:givenName Ashray B.
    142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011675624160.73
    143 rdf:type schema:Person
    144 sg:person.0726366600.25 schema:affiliation grid-institutes:grid.239585.0
    145 schema:familyName Carvajal
    146 schema:givenName Richard D.
    147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25
    148 rdf:type schema:Person
    149 sg:pub.10.1007/s10637-016-0377-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040010442
    150 https://doi.org/10.1007/s10637-016-0377-0
    151 rdf:type schema:CreativeWork
    152 sg:pub.10.1038/nature07586 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018711414
    153 https://doi.org/10.1038/nature07586
    154 rdf:type schema:CreativeWork
    155 sg:pub.10.1038/nature08911 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025477952
    156 https://doi.org/10.1038/nature08911
    157 rdf:type schema:CreativeWork
    158 sg:pub.10.1038/ncomms10156 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043043138
    159 https://doi.org/10.1038/ncomms10156
    160 rdf:type schema:CreativeWork
    161 sg:pub.10.1038/ncomms10615 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006408398
    162 https://doi.org/10.1038/ncomms10615
    163 rdf:type schema:CreativeWork
    164 sg:pub.10.1038/ng.2523 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004149711
    165 https://doi.org/10.1038/ng.2523
    166 rdf:type schema:CreativeWork
    167 sg:pub.10.1038/ng.2674 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034318026
    168 https://doi.org/10.1038/ng.2674
    169 rdf:type schema:CreativeWork
    170 sg:pub.10.1038/nm.4098 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046002996
    171 https://doi.org/10.1038/nm.4098
    172 rdf:type schema:CreativeWork
    173 sg:pub.10.1038/nrc1387 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015516287
    174 https://doi.org/10.1038/nrc1387
    175 rdf:type schema:CreativeWork
    176 sg:pub.10.1038/onc.2013.418 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019096299
    177 https://doi.org/10.1038/onc.2013.418
    178 rdf:type schema:CreativeWork
    179 sg:pub.10.1038/s41467-017-02428-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1100179001
    180 https://doi.org/10.1038/s41467-017-02428-w
    181 rdf:type schema:CreativeWork
    182 sg:pub.10.1038/s41467-019-13348-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1123153093
    183 https://doi.org/10.1038/s41467-019-13348-2
    184 rdf:type schema:CreativeWork
    185 sg:pub.10.1038/s41540-019-0107-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1120337444
    186 https://doi.org/10.1038/s41540-019-0107-2
    187 rdf:type schema:CreativeWork
    188 sg:pub.10.1038/s41568-021-00340-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1136443344
    189 https://doi.org/10.1038/s41568-021-00340-6
    190 rdf:type schema:CreativeWork
    191 sg:pub.10.1038/s41588-019-0440-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1117623763
    192 https://doi.org/10.1038/s41588-019-0440-9
    193 rdf:type schema:CreativeWork
    194 sg:pub.10.1038/sj.bjc.6602598 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051793685
    195 https://doi.org/10.1038/sj.bjc.6602598
    196 rdf:type schema:CreativeWork
    197 sg:pub.10.1038/sj.bjc.6605714 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013296980
    198 https://doi.org/10.1038/sj.bjc.6605714
    199 rdf:type schema:CreativeWork
    200 sg:pub.10.1186/s12885-021-07865-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1135369909
    201 https://doi.org/10.1186/s12885-021-07865-x
    202 rdf:type schema:CreativeWork
    203 sg:pub.10.1186/s12943-018-0795-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1101066796
    204 https://doi.org/10.1186/s12943-018-0795-z
    205 rdf:type schema:CreativeWork
    206 grid-institutes:grid.239585.0 schema:alternateName Columbia University Irving Medical Center, New York, New York, USA
    207 schema:name Columbia University Irving Medical Center, New York, New York, USA
    208 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...